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Abstract: Optimal treatment selection for localized renal tumors is challenging due to their variable
biological behavior and limited ability to pre-operatively assess their aggressiveness. We investigated
hyperpolarized (HP) 13C pyruvate MRI to noninvasively assess tumor lactate production and
compartmentalization, which are strongly associated with renal tumor aggressiveness. Orthotopic
tumors were created in mice using human renal cell carcinoma (RCC) lines (A498, 786-O, UOK262)
with varying expression of lactate dehydrogenase A (LDHA) which catalyzes the pyruvate-to-lactate
conversion, and varying expression of monocarboxylate transporter 4 (MCT4) which mediates lactate
export out of the cells. Dynamic HP 13C pyruvate MRI showed that the A498 tumors had significantly
higher 13C pyruvate-to-lactate conversion than the UOK262 and 786-O tumors, corresponding to
higher A498 tumor LDHA expression. Additionally, diffusion-weighted HP 13C pyruvate MRI
showed that the A498 tumors had significantly higher 13C lactate apparent diffusion coefficients
compared to 786-O tumors, with corresponding higher MCT4 expression, which likely reflects more
rapid lactate export in the A498 tumors. Our data demonstrate the feasibility of HP 13C pyruvate
MRI to inform on tumor lactate production and compartmentalization, and provide the scientific
premise for future clinical investigation into the utility of this technique to noninvasively interrogate
renal tumor aggressiveness and to guide treatment selection.
Keywords: hyperpolarized 13C magnetic resonance imaging (HP 13C MRI); dynamic nuclear
polarization (DNP); aerobic glycolysis; lactate dehydrogenase (LDH); lactate efflux; renal cell
carcinoma (RCC)
1. Introduction
The increased utilization of medical imaging has led to a significant increase in the incidental
detection of renal tumors, most of which are renal cell carcinomas (RCCs) [1,2]. Many of these
incidentally detected RCCs are localized small tumors, which account for 40–50% of newly diagnosed
renal tumors [1]. There is increasing recognition of the biological heterogeneity of these tumors [1,3,4],
and their management options have evolved over time and now include minimally- and non-invasive
approaches, such as ablation and active surveillance, in addition to traditional surgical resection [5].
However, the selection of optimal management approaches for an individual with these renal tumors
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can be challenging due to a lack of reliable means for estimation of the relative risks and benefits of
each approach. This is largely related to the limited ability to pre-operatively predict the histology,
grade and aggressiveness of renal tumors. For example, current imaging techniques cannot reliably
differentiate low grade, indolent RCCs which are amenable to active surveillance from localized but
high grade and potentially aggressive RCCs that require surgery. As a result, many indolent RCCs are
likely over-treated with surgery, as the increased detection of RCCs has not translated into a decrease
in cancer-specific deaths [1,6]. Additionally, certain benign renal tumors including oncocytomas
and lipid-poor angiomyolipomas cannot be reliably differentiated from RCCs by imaging, and are
frequently unnecessarily resected [7–9]. Renal tumor biopsies also have limitations, including up to
20% of biopsies being non-diagnostic [10,11], and frequent under-grading of RCCs [12,13], which is
problematic for selection between active surveillance versus definitive treatment.
Increasing evidence has shown that RCC is strongly linked to abnormal metabolism. In particular,
increased glycolysis with lactate production and efflux, which is thought to promote acid-mediated
matrix degradation and tumor invasiveness [14], is a dominant metabolic feature of aggressive RCCs
and a potential therapeutic target [15–19]. Lactate dehydrogenase A (LDHA) gene encodes the enzyme
that catalyzes the conversion of pyruvate to lactate. Multiple studies of RCC tissues have shown that
tumor LDHA expression correlates with RCC grade and clinical stage, and high tumor LDHA is a
strong independent predictor of tumor progression and poor patient survival [20–22]. To maintain
intracellular acid-base balance, cancer cells preferentially utilize the monocarboxylate transporter 4
(MCT4) to export lactate out of the cells. This is essential for preventing a decrease in cytosolic pH,
and for maintaining high level of glycolysis and lactate production, thereby supporting cancer cell
growth and invasion [23,24]. Prior studies have shown that high MCT4 expression is associated with
more aggressive RCCs and worse progression-free survival [25,26]. These studies provide the rationale
for metabolic imaging of lactate production and export as a noninvasive means to inform on renal
tumor aggressiveness.
Hyperpolarized (HP) 13C magnetic resonance imaging (MRI) allows rapid, noninvasive,
pathway-specific investigation of real-time metabolic and physiological processes that were previously
inaccessible by imaging. Hyperpolarization, achieved through the dynamic nuclear polarization
(DNP) technique [27], provides unprecedented gains in sensitivity (>10,000-fold signal increase)
for imaging 13C-labeled bio-molecules. Dynamic HP 13C pyruvate MRI has been used to monitor
the LDHA-mediated increased pyruvate-to-lactate conversion that occurs in several aggressive
cancers [28–31]. In addition, recent studies have also combined diffusion-weighted acquisitions with
HP 13C MRI to interrogate the compartmentalization (i.e., intra- versus extracellular compartment)
of 13C metabolites including lactate, thereby providing information on the metabolite transporter
and microenvironment [32–38]. In this study, we utilized dynamic HP 13C MRI to investigate the
pyruvate-to-lactate conversion in a murine orthotopic RCC model, with correlation to tumor LDHA
expression. Additionally, because rapid lactate export has been associated with more aggressive RCCs,
we investigated the lactate compartmentalization via measurements of 13C lactate apparent diffusion
coefficients (ADCs) by diffusion-weighted HP 13C MRI.
2. Results
2.1. Orthotopic Tumor Characteristics on 1HMRI and on Histology
The growth characteristics of the orthotopic tumors derived from three human RCC cell lines
with varying expression of LDHA and MCT4 is summarized in Supplemental Table S1. The A-498
tumors consistently grew faster (reaching a volume of 0.1 cc under 4 weeks) than the UOK262 and
786-O tumors (reaching a volume of 0.1 cc at ~5.5 weeks). HP 13C MRI was performed when the tumor
reached a volume >0.4 cc to minimize partial volume averaging with adjacent renal parenchyma.
There was no significant difference in tumor volume among the three cell lines at the time of HP 13C
pyruvate MRI. Figure 1A shows representative T2 weighted anatomic images of the orthotopic tumors.
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H&E of tumor sections demonstrated that the A-498 tumors were qualitatively less cellular than
the UOK262 and 786-O tumors (Figure 1B). Quantitative image analysis of the H&E sections confirmed
that the A-498 tumors had significantly lower mean cellularity, represented by the % area covered by
nuclei, when compared to the other tumors (A-498: 16 ± 0.5%; 786-O: 23 ± 0.8%; UOK262: 23 ± 1.0%;
p-values < 0.0001) (Figure 1C). The size of the nuclei was not significantly different among the tumors
derived from the three cell lines. As apparent diffusion coefficients (ADCs) from 1H diffusion-weighted
MRI have been shown to inversely correlate with RCC cellularity in patients [39], we also correlated the
1H ADCs of the orthotopic tumors to tumor cellularity as estimated on the H&E sections, and found a
significant inverse correlation (r = 0.69, p = 0.0002) (Figure 1D).
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Figure 1. Orthotopic tumor on 1H MRI and histology. (A) Representative T2-weighted anatomic images
of the tumors outlined by yellow dashed lines. (B) Representative H&E staining of the tumor secti ns
shows qualitatively lower cellularity in the A-498 tumors (at 20× magnification). (C) Qua titative
image alysis of the H&E sections confirms that the A-498 tumors have significantly lower mean %
area covered by nuclei, a measure of cellularity, compared to the other tumors (p < 0.0001). The nuclei
size is not significantly different among the three tumors. (D) The ADCs from 1H diffusion-weighted
MRI are significantly inversely correlated to tumor cellularity (r = 0.69, p = 0.0002). * denotes statistically
significant change (p < 0.05).
2.2. Dynamic HP 13C MRI to Interrogate Pyruvate-to-Lactate Conversion
Figure 2 shows representative HP 13C pyruvate and 13C lactate images of tumors overlaid on
T2-weighted anatomic images, and dynamic curves of HP 13C pyruvate and 13C lactate signal over
time in an A-498 tumor. The 13C pyruvate signal peaks around 12 s following the start of the injection.
Supplemental Figure S1 summarizes the 13C pyruvate dynamics for the tumors derived from the three
different cell lines, showing a similar peak 13C pyruvate signal among the tumors, and a slightly longer
duration of the 13C pyruvate signal in the A498 tumors. Supplemental Figure S2 shows representative
images of HP 13C signal overlaid on T2-weighted anatomic images without tumor segmentation.
Figure 3A shows 13C pyruvate-to-lactate conversion in A-498 (n = 8), UOK262 (n = 7), and 786-O (n = 8)
tumors, represented by the 13C lactate area-under-the-curve/maximum pyruvate (13C LacAUC/Pyrmax),
and normalized by the tumor 1H ADC to adjust for the differential cellularity of the tumors. Since the
tumor 1H ADC is a surrogate for cell density (Figure 1D), the 13C pyruvate-to-lactate conversion in
tumors with higher cellularity and corres onding lower 1H ADC is scaled to take into account
the c llularity, thus permitting a more accurate comparison of relative 13C metabolism among
the tumors. The tumor HP 13C LacAUC/Pyrmax ratios without the 1H ADC scaling are shown in
Supple ental Figure S3. One way ANOVA with po t-hoc comparisons shows that he normalized
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13C pyruvate-to-lactate conversion was significantly higher in the A-498 tumors (2.70 ± 0.25 × 10−3)
compared to the UOK262 tumors (1.90 ± 0.23 × 10−3, p = 0.02) and 786-O tumors (2.05 ± 0.15 × 10−3,
p = 0.04). The tumor LDHA expression (relative to β-actin) showed a similar trend with A-498 tumors
having significantly higher LDHA expression than the 786-O tumors (400 ± 51% vs. 247 ± 47%,
p = 0.033). The LDHA expression of A-498 was also higher than that of UOK262 tumors, with a p-value
approaching significance (400 ± 51% vs. 280 ± 43%, p = 0.071) (Figure 3B).
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Figure 2. Representative tumor HP 13C pyruvate and 13C lactate images and dynamic curves of HP
13C pyruvate and 13C lactate signal over time in an A-498 tumor. (A) T2-weighted anatomic image
with the tumor outlined by dashes. (B), (C) Tumor HP 13C pyruvate and lactate image overlaid on
the T2-weighted anatomic image at maxi um signal intensity at 12 and 15 s, respectively. The 13C
pyruvate sign l in (B) is not corrected for th sm l flip a . (D) Mean tumor l intensity of
HP 13C pyruvate and lactate over time. 13C pyruvate signal is flip a gle corrected. 13C lactate signal
typically peaks approximately 3–6 s following the peak of the 13C pyruvate signal.
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Figure 3. Dynamic HP 13C MRI to interrogate pyruvate-to-lactate conversion in orthotopic RCC
tumors. (A) Tu or 13C pyruvate-to-lactate conversion, represented by LacAUC/Pyrmax, normalized
by the tum r 1H ADC t adjust for the differential cell la ity of the tumors. The normalized
pyruvate-to-lactate conversion was significantly higher in the A-498 tumors compared to the UOK262
tumors (p = 0.02) and 786-O tumors (p = 0.04). (B) The LDHA expression of A498 tumors was
significantly higher than that of 786-O tumors (p = 0.03). The LDHA expression of A498 was also higher
than that of UOK262 tumors, with a p-value approaching significance (p = 0.07). * denotes statistically
significant change (p < 0.05).
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2.3. Diffusion Weighted HP 13C MRI to Interrogate Lactate Compartmentalization
Figure 4A shows representative tumor 13C pyruvate and 13C lactate ADC maps from
diffusion-weighted HP 13C MRI overlaid on the T2-weighted anatomic images. One-way ANOVA
with post-hoc comparisons shows that 13C lactate ADC values were significantly higher in the A-498
tumors compared to the 786-O tumors (0.495 ± 0.018 × 10−3 vs. 0.421 ± 0.027 × 10−3 mm2/s,
p = 0.03). The 13C lactate ADC values were also higher in the A-498 tumors compared to the
UOK262 tumors, though the p-value did not reach statistical significance (0.495 ± 0.018 × 10−3 vs.
0.443 ± 0.024 × 10−3 mm2/s, p = 0.10) (Figure 4B). The 13C pyruvate ADC values were approximately
2-fold higher than the lactate ADC values, and there was no significant difference in the 13C pyruvate
ADC values among the three types of tumors studied (A-498: 1.120 ± 0.115 × 10−3 mm2/s; UOK262:
0.977 ± 0.058 × 10−3 mm2/s; 786-O: 0.916 ± 0.037 × 10−3 mm2/s, p value > 0.20) (Figure 4B).
MCT4 is the key exporter of lactate out of the cells; the MCT4 staining intensity in the A-498 tumors
(9.87 ± 0.63%) was significantly higher compared to the UOK262 (5.87 ± 0.68%, p = 0.001) and 786-O
tumors (4.4 ± 0.47%, p = 0.0001) (Figure 4B).
There was no significant correlation between tumor 13C lactate ADCs and normalized
pyruvate-to-lactate conversion (r = 0.288, p = 0.32).
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Figure 4. Diffusion-weighted HP 13C MRI to interrogate 13C lactate compartmentalization in orthotopic
RCC tumors (A-498 (n = 8), UOK262 (n = 7), and 786-O (n = 8) tumors). (A) Representative 13C pyruvate
and 13C lactate ADC maps of tumors from diffusion-weighted HP 13C MRI overlaid on the T2-weighted
anatomic images. (B) The 13C lactate ADC values were significantly higher in the A-498 compared
to the 786-O tumors (p = 0.03). The 13C lactate AD values were also higher in the A-498 tumors
compared to the UOK262 tumors, though the p-value did not reach statistical significance (p = 0.10).
The 13C pyruvate ADC values were not significantly different betw en any of the tumors. MCT4
staining in the A-498 tumors was significantly higher compared to th UOK262 and 786-O tumors
(p = 0.001, p = .0001, respectiv ly). * d notes statistically ignificant change (p < 0.05).
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3. Discussion
Localized small renal cell carcinomas (RCCs) are increasingly detected incidentally at imaging.
There is an unmet clinical need for new biomarkers to improve the noninvasive determination of tumor
aggressiveness in order to guide treatment selection. In a murine orthotopic model of human RCC,
we demonstrated the feasibility of HP 13C pyruvate MRI as a noninvasive means to inform on tumor
lactate production and compartmentalization, which are strongly associated with aggressive RCCs.
We found that the A-498 tumors had significantly higher 13C pyruvate-to-lactate conversion than
the UOK262 and 786-O tumors, with a corresponding trend in the tumor LDHA expression. We noted
that while the tumor 13C pyruvate-to-lactate conversion was significantly different between the A-498
and UOK262 tumors, the corresponding difference in the LDHA expression between the two tumors
did not reach statistical difference (p = 0.07). As the tumor 13C pyruvate-to-lactate conversion was
measured over a much larger tumor volume compared to the LDHA expression that was assayed from a
very small sample of the harvested tumors; it is possible that any potential intra-tumoral heterogeneity
might explain the discrepancy. Nonetheless, these data demonstrate the feasibility of dynamic HP 13C
MRI to noninvasively inform on tumor LDHA expression. This is clinically relevant because multiple
prior tissue studies have reported the association between LDHA-mediated lactate production and
tumor aggressiveness in RCCs. For example, proteomic and metabolomics analyses of human RCC
tissues have shown that lactate was increased in a grade-dependent manner, with high grade RCCs
having 2-fold higher lactate than low grade ones [19]. Other studies have demonstrated that RCC
LDHA mRNA and protein expression are positively correlated with histological grade and clinical
stage, and high LDHA expression is a strong independent predictor of tumor progression and poor
survival [20–22]. Therefore, by monitoring in vivo the LDHA-mediated pyruvate-to-lactate conversion,
HP 13C pyruvate MRI may improve the noninvasive stratification of RCC grade and aggressiveness.
We found that the orthotopic tumors derived from the A-498, UOK262 and 786-O cells have
different cellularity, with the A-498 tumors having significantly lower cellularity compared to the other
two tumors. We also found a significant inverse correlation between the tumor 1H ADC from 1H
diffusion-weighted MRI and tumor cellularity as estimated from the H&E sections. While 1H ADC can
be influenced by a number of other factors including cell membrane integrity and viscosity, our data
are in agreement with those from prior clinical studies of 1H diffusion-weighted MRI in RCCs [39],
and support the use of 1H ADC for in vivo assessment of cellularity. For tumors with higher cellularity
per given volume of tumor, the observed hyperpolarized 13C pyruvate-to-lactate conversion is expected
to reflect both the cellular metabolism (i.e., LDHA mediated pyruvate to lactate conversion) as well as
cellularity. We therefore normalized the tumor 13C pyruvate-to-lactate conversion by multiplying by
the tumor 1H ADCs to adjust for the cellularity difference between the tumors in our study. Notably,
diffusion-weighted 1H MRI is routinely done in the clinic, and diffusion-weighted 1H MRI and HP
13C MRI can be readily integrated into a multi-parametric MRI exam. Our current data provide the
motivation for future work to validate and further refine such an approach incorporating cellularity in
the assessment of tissue metabolism with the goal of a more accurate interpretation and comparison of
metabolism in tumors with variable cellularity.
In our study, we used maximum pyruvate (Pyrmax) to normalize any variability in the 13C
pyruvate polarization and delivery to the tumors, analogous to the use of maximum standardized
uptake value (SUV) in positron emission tomography (PET) to remove the variability in the injected
dose. We did not use pyruvate area-under-the-curve (PyrAUC) for normalization, as PyrAUC will likely
be impacted by tumor cellularity. Because pyruvate is rapidly converted to lactate inside the cells,
the observed HP 13C pyruvate signal is presumed to be predominantly in the extracellular space.
As such, we hypothesize that less cellular tumors, such as the A-498 tumors in our study, have larger
extracellular space and retain more 13C pyruvate signal during the course of the dynamic acquisition,
thereby impacting PyrAUC. This is supported by the longer duration of the 13C pyruvate signal in the
A498 tumors (Supplementary Figure S1).
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In addition to interrogating the tumor HP 13C pyruvate-to-lactate conversion, we also investigated
the 13C lactate compartmentalization using diffusion-weighted 13C MRI. Recent work has shown that
ADCs of HP 13C metabolites can provide information about the localization of these molecules
in the tissue microenvironment, with intra-cellular metabolites having lower 13C ADCs than the
extra-cellular metabolites [33,34]. Relevant to RCCs, a prior in vitro study has reported that cells from
an aggressive RCC rapidly exported more lactate out of the cells via the monocarboxylate transporter
MCT4 compared to cells from an indolent RCC [28]. Additionally, increased lactate efflux was also
observed in RCCs compared to benign renal tumors in an ex vivo HP 13C MR study of patient-derived
renal tumor tissue slices [40]. Therefore, 13C lactate ADCs derived from diffusion-weighted
HP 13C MRI, by informing on the lactate compartmentalization (relative extra- and intra-cellular
distribution), may report on MCT4 transporter expression and provide an additional biomarker of
tumor aggressiveness. Indeed, another previous in vitro study of RCC cells demonstrated the ability
of diffusion-weighted 13C MR to assess in real-time the intra- and extra-cellular 13C lactate pools and
to probe membrane transport via MCT4 [34]. In that study, the intracellular 13C lactate ADCs for RCC
cells ranged from 0.17 ± 0.03 × 10−3 mm2/s to 0.19 ± 0.03 × 10−3 mm2/s, while the extracellular 13C
lactate ADCs ranged from 0.57 ± 0.10 × 10−3 mm2/s to 0.63 ± 0.06 × 10−3 mm2/s. In our current
study, we found that the RCC tumor in vivo 13C lactate ADCs ranged from 0.421± 0.027× 10−3 mm2/s
to 0.495 ± 0.018 × 10−3 mm2/s. These in vivo 13C lactate ADCs are between the previously reported
intra-cellular and extra-cellular 13C lactate ADCs in cell studies, and reflect a composite of intra- and
extra-cellular lactate ADCs. Differences in the tumor in vivo 13C lactate ADCs can therefore inform
on the relative intra- vs. extra-cellular compartmentalization of lactate. We found that the 13C lactate
ADCs were significantly higher in the A-498 tumors compared to the 786-O tumors. As A-498 tumors
have higher MCT4 as quantified by antibody staining, they likely have more rapid 13C lactate export
to the extracellular compartment, and therefore higher 13C lactate ADCs. The 13C lactate ADC values
were also higher in the A-498 tumors compared to the UOK262 tumors, though the p-value did not
reach statistical significance (p = 0.10). This may be related to the limited sensitivity of measuring 13C
lactate ADC at a single time point, and could be improved by dynamic 13C ADC measurements [34,37]
that aim to monitor the real-time changes in 13C lactate compartmentalization due to lactate efflux.
It is possible that the lower cellularity of the A-498 tumors may also contribute to their higher 13C
lactate ADCs, though the cellularity difference alone is not likely to account for the differences in the
observed tumor 13C lactate ADCs. The observed 13C pyruvate signal is assumed to be predominantly
in the extracellular space, which is supported by the observed tumor in vivo 13C pyruvate ADCs
that were similar to extracellular 13C pyruvate ADCs of 1.2 × 10-3 mm2/s measured in a cell culture
system [34]. As such, the 13C pyruvate ADCs are likely similarly influenced by cellularity. However,
we did not find significant differences in the 13C pyruvate ADC values among the three tumors,
indicating that the observed 13C lactate ADC differences between the tumors would not be explained
by the cellularity differences alone. The relative contribution to tumor 13C lactate ADC in vivo from
lactate export and cellularity needs to be evaluated in future studies. Nonetheless, our results suggest
that 13C lactate ADCs may provide useful information on tumor lactate compartmentalization. In this
study, we did not find a significant correlation between the tumor 13C pyruvate-to-lactate conversion
and 13C lactate ADC values, suggesting that they may provide non-redundant information in vivo.
Future studies are needed to evaluate the utility of 13C lactate ADCs, alone or in combination with
pyruvate-to-lactate conversion in stratifying renal tumor grade and aggressiveness.
Novel imaging biomarkers that can reliably diagnose RCCs and differentiate low from high
grade RCCs are of great clinical interest given the rising incidence of incidentally discovered renal
tumors and an increasing array of more conservative treatment options [5]. Neither tumor size nor
conventional imaging features are able to reliably predict the biological behavior of localized small renal
tumors [9,41,42]. Accurate assessment of RCC grade via biopsy is also challenging due to potential
intra-tumor heterogeneity [43], and the definition of the Fuhrman nuclear grade of RCC as the highest
grade within the tumor even if it only represents a focal region of the tumor. These factors likely
Cancers 2018, 10, 313 8 of 14
accounted for the reported under-grading of RCCs using percutaneous biopsies [12,13]. Given that
elevated glycolysis with increased lactate production and efflux is central to RCC malignant behavior,
HP 13C pyruvate metabolic MRI has the potential to improve the identification of potentially aggressive
tumors. Our data from the orthotopic RCC model demonstrate the feasibility of the technique to
noninvasively inform on tumor lactate production and compartmentalization, and support its clinical
translation for assessing renal tumor aggressiveness and for guiding treatment selection. Notably,
the safety and feasibility of HP 13C pyruvate MRI has already been demonstrated in the phase I clinical
trial in prostate cancer patients [44], and in initial human cardiac study [45]. Additionally, work is
ongoing to develop multi-channel 13C coil to provide optimal signal reception in abdominal organs for
clinical studies.
Our study has several limitations. One limitation is that the tumors generated in this study do
not per se represent low versus high grade human RCCs. In our experience, the cell lines derived
from indolent human RCCs do not produce robust tumors in vivo in mouse models. Additionally,
cell lines of benign human renal tumors are not available. Nonetheless, by investigating the in vivo
metabolism of tumors created from human RCC cell lines of differential LDHA and MCT4 expression,
which are implicated in the biological behavior of RCCs, we have provided initial data indicating the
potential utility of HP 13C pyruvate MRI for stratifying tumor aggressiveness and the rationale for
future clinical investigation. As already discussed above, another limitation of the study is that the
observed in vivo tumor 13C lactate ADC is a composite of the intra- and extra-cellular lactate ADC,
and may be influenced by both lactate export via MCT4 as well as tumor cellularity. Further work to
acquire dynamic 13C ADC measurements and to improve the modeling are needed to estimate the
tumor intracellular and extracellular lactate fractions, and to refine the interpretation of the observed
in vivo tumor 13C lactate ADC and its relationship to MCT4. Furthermore, it currently requires two
separate 13C pyruvate injections to acquire data for measurements of 13C pyruvate-to-lactate conversion
and 13C lactate ADCs. Work is ongoing to combine rapid dynamic imaging for pyruvate-to-lactate
conversion measurements with a motion-sensitizing gradient for the simultaneous investigation of
lactate compartmentalization.
4. Materials and Methods
4.1. Cell Lines
The A-498 and 786-O cell lines were derived from patients with the clear cell subtype of RCCs,
and purchased from American Tissue Culture Collection (ATCC, Manassas, VA, USA). The UOK262
cell line was derived from a patient with hereditary leiomyomatosis renal cell carcinoma (HLRCC),
which is a papillary RCC subtype and is characterized by mutation of the tricarboxylic acid cycle
enzyme fumarate hydratase (FH) [46]. UOK262 cells were a kind gift from Dr. W. Marston Linehan
(National Cancer Institute, Bethesda, MD, USA). These cell lines were chosen because our preliminary
cell studies showed that they have differential LDHA and MCT4 expression (Supplementary Figure S4).
Cells were grown in Dulbeco’s Modified Eagle’s medium (DMEM) with 4.5 g/L glucose. The cells
were passaged serially and were used between passages 2–12 and at 60–80% confluency for orthotopic
(subrenal) tumor implantation.
4.2. Murine Orthotopic RCC Model
All procedures were approved by our Institutional Animal Care and Use Committee on 18
June 2016 (Protocol No: AN138870). Four to six week-old male Rag2/IL2rg double knockout mice
(B10;B6-Rag2tm1FwaIL2rgtm1wjl) were purchased from Taconic Farms or Jackson Laboratories. The
Rag2/IL2rg double knockout mice lack T cells, B cells and natural killer cells, and are a useful model
for creating xenograft tumors. We selected the renal subcapsular location for tumor implantation
to more closely resemble the native tissue environment of renal tumors in patients. Prior studies
have noted that the renal subcapsular location provides a superior environment for growth of tumors
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derived from human RCC cell lines and for studying their biology [47,48]. The mice were anesthetized
using 2% inhalant isoflurane and the human RCC cells described above were implanted under the
renal capsule using standard procedures. Briefly, a small (1–2 cm) incision was made in the mid-left
flank of the mouse to expose the left kidney. An insulin syringe was inserted under the renal capsule,
and approximately 5–6 million RCC cells in phosphate buffered solution were injected. The kidney
was then placed back inside the abdominal cavity and the wound was sutured close. The mice
were screened for tumor growth using T2-weighted 1H MRI weekly. A-498 (n = 8), UOK262 (n = 7),
and 786-O (n = 8) tumors underwent HP 13C MRI and subsequent tissue analyses. Table S1 shows the
average volume of the orthotopic tumors at the time of HP 13C MRI.
4.3. 1H and HP 13C MRI
Tumor-bearing mice were imaged on a 14.1 T vertical bore micro-imaging system (Agilent, Palo
Alto, CA, USA) equipped with high performance gradients (maximum gradient strength = 100 G/cm,
maximum slew-rate = 556 G/cm/ms) and a dual tuned 40 mm diameter volume coil for 1H and 13C
imaging (M2M, Australia). Mice were anesthetized with 1–2% inhalant isoflurane. A tail vein catheter
was placed for venous access. High resolution respiratory-gated T2-weighted 1H images were obtained
first for anatomic references using a spin echo sequence and the following parameters: matrix size,
256 × 192; field-of-view, 32 × 32 mm; repetition time, 1.6 s; echo time, 20 ms; slice thickness, 1 mm;
number of slices, 16–20. 1H diffusion weighted images were also acquired through the kidneys and
orthotopic tumors using the following parameters: matrix size, 256 × 192; field of view, 32 × 32 mm;
slice thickness, 2 mm; b-values of 25, 180, 323, 508 s/mm2.
[1-13C]pyruvate was polarized as previously reported using a HyperSense polarizer (Oxford
Instrument, UK) [28]. Briefly, 24 µL [1-13C]pyruvic acid was mixed with GE trityl radical (Oxford
Instruments, UK) and 1.5 mM Gd-DOTA and polarized for 1 hour, and then dissolved in isotonic
buffer with equivalents of NaOH to yield a pH of 6.5–8. Each mouse then underwent two HP 13C
MR acquisitions following two separate injections of 300 µL of 80 mM HP [1-13C]pyruvate: a 2D
dynamic echo-planar imaging (EPI) acquisition to interrogate the pyruvate-to-lactate conversion, and a
diffusion-weighted 13C acquisition to interrogate lactate compartmentalization. HP [1-13C]pyruvate
was injected via tail vein in 12–14 s.
The 2D dynamic EPI acquisition [49] was performed with spectrally and spatially selective RF
pulses to image HP 13C pyruvate and 13C lactate sequentially using the following parameters: an
8 mm thick axial slab centering on the orthotopic tumor; repetition time, 3 s; matrix size, 16 × 16;
field-of-view, 32 × 32 mm; a constant flip angle of 90◦ for 13C lactate; variable flip angles (from 3–90◦)
for 13C pyruvate to efficiently use the hyperpolarized magnetization in the presence of metabolic
conversion [50]; a total of 20 time points with the acquisition initiated at 6 s from the start of the
injection. The diffusion-weighted HP 13C acquisition was performed with spectrally and spatially
selective 30◦ RF pulse for lactate and pyruvate, with all the lactate b-value images being acquired
before acquiring the pyruvate b-value images, and the following parameters: an 8 mm thick axial
slab centering on the orthotopic tumor; matrix size, 16 × 16; field-of-view, 32 × 32 mm; interleaved
b-values, 50, 300, 600, 1500, 1000 and 2000 s/mm2; diffusion gradient duration (δ), 5 ms; gradient
separation, ∆ = 22.4 ms; and respiratory gating (two b-values/breath) to minimize signal loss from
bulk motion. The single time-point diffusion-weighted HP 13C acquisition was initiated at 15 s from
the start of the injection.
4.4. MRI Data Analysis
All image processing and analysis were performed using MATLAB (Mathworks, Natick, MA,
USA), and IDL based in-house software BRIMAGE. T2-weighted images were used to calculate
the tumor volumes by drawing regions of interest (ROIs) on all slices covering the tumor. From
the 1H diffusion-weighted images, 1H ADC maps were calculated using mono-exponential fitting
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( SbS0 = e
(−b×ADC)), where Sb is the signal intensity at a given b value, and S0 the signal intensity for
b = 0 s/mm2. The mean tumor 1H ADCs were estimated by ROIs from all tumor bearing slices.
All HP 13C data were zero filled to 32 × 32. The 2D dynamic spectral spatial 13C data were
corrected for RF flip angles, and the area under the curve (AUC) of 13C lactate to maximal pyruvate
signal (LacAUC/Pyrmax) was calculated from ROIs drawn over the tumor. To account for the different
cellularity between the tumors in vivo, which could impact the comparison of cellular pyruvate
metabolism, tumor 13C pyruvate-to-lactate conversion was scaled by the tumor 1H ADC. 1H ADC
has been shown previously to inversely correlate with RCC cellularity in patients [39]. As such, for
example, the 13C pyruvate-to-lactate conversion in tumors with higher cellularity and corresponding
lower 1H ADC is scaled by multiplying LacAUC/Pyrmax by the mean tumor 1H ADC to take into
account the cellularity.
For the diffusion-weighted 13C MR acquisition, the same mono-exponential fitting as above was
performed to compute the mean 13C lactate and 13C pyruvate ADC of the tumors.
4.5. LDHA Expression Assay
Following imaging, mice were euthanized and the renal tumors were rapidly dissected. A portion
of the tumor was immediately formalin-fixed for hematoxylin and Eosin (H&E) and MCT4 staining.
The rest was snap frozen and stored at −80 ◦C for subsequent LDHA expression assay.
mRNA expression of LDHA was quantified using qRT-PCR. In brief, total RNA was extracted
from the tumor tissue using an RNAeasy kit (Qiagen, Germantown, MD, USA). Reverse transcription
was performed using an iScript cDNA Synthesis kit (BioRad Laboratories, Hercules, CA, USA), and the
subsequently generated cDNA was used for PCR in triplicate with TaqMan chemistry on the PikoReal
system (Thermo Fisher Scientific, Waltham, MA, USA. Primers for the genes were obtained from
Thermo Fisher Scientific (Waltham, MA, USA). β-Actin was used as the reference gene for expression
level quantification.
4.6. H&E and MCT4 Staining, and Imaging Analysis
Standard H&E as well as anti-MCT4 staining (rabbit, polyclonal IgG, Santa Cruz Biotechnology
Inc, USA) were performed on tumor sections (3 µm thick) de-paraffinized overnight by incubation at
55 ◦C and in descending grade of ethanol using standard protocols. Heat-induced epitope retrieval
was performed with citrate buffer at pH 6.0 for 20 min and cooled, followed by endogenous quenching
with 30% H2O2 for 15 min. For MCT4 staining, tissue sections were incubated with rabbit polyclonal
primary antibody SC-376140 anti MCT4 in 1:100 dilution at 4 ◦C overnight, followed by incubation
with rabbit secondary antibody/ HRP at 1:200 dilution for 20 min at room temperature. The stained
sections were then imaged with a Nikon 6D microscope under bright-field illumination using a 40×
power objection yielding a 0.15 µm in-plane resolution.
The H&E images were used to estimate tumor cellularity using a home built CellProfiler pipeline
(Figure S5) [51]. Briefly, the hematoxylin stain was first isolated by un-mixing the colors in order to
allow the counting of the number of nuclei. The image masks of the nuclei were then created after
Otsu thresholding, prescribing the cell diameter, and optimizing the de-clumping of objects. Finally,
the cellularity of the tumors was estimated by calculating the percentage area of the image covered by
nuclei. All of the images were obtained at the same resolution. The accuracy of the estimated cellularity
of the tumor obtained using the method above was also manually verified in a subset of cases.
The MCT4 images were analyzed using the Image analysis toolbox in MATLAB (Figure S6). The
HSV (hue-saturation-value) color scale was used to threshold the images and create binary images of
the MCT4 stain using an interval of [0, 0.169] for hue (H) to capture the brown color stain, interval of
[0.189, 1.000] for saturation (S), and restricting the value (V) to within the 16th percentile to account
for the different illumination. Using the masks, the number of stained (MCT4) pixels was calculated
as a percent of the total tissue area after sampling three different regions for each tumor, and was
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represented as the mean % MCT4 staining for each tumor. More detailed methodologies for the image
analyses are described in the Supplementary data.
4.7. Statistical Analysis
Data were presented as mean ± standard error of the mean. One-way ANOVA with post hoc
tests were used to assess the difference among relevant groups. Corrections for multiple comparisons
were made by controlling for false discovery rate (q < 0.05) using the two-stage step-up method of
Benjamin, Krieger and Yekutieli. Correlation analyses were performed using Pearson correlation tests.
p-values < 0.05 were considered statistically significant. All statistical tests were performed using
PRISM (GraphPad, La Jolla, CA, USA).
5. Conclusions
In summary, we have demonstrated the feasibility of HP 13C pyruvate MRI to noninvasively
interrogate tumor lactate production and compartmentalization in a murine orthotopic model of
human RCCs, and to inform on tumor LDHA and MCT4 expression which are implicated in tumor
aggressiveness. Our data provide the scientific premise for future clinical investigation into the utility
of HP 13C pyruvate MRI to noninvasively differentiate benign renal tumors from RCCs and to stratify
indolent from aggressive RCCs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/9/313/s1.
Figure S1: Hyperpolarized 13C pyruvate dynamics in orthotopic tumors; Figure S2: Representative non-segmented
images of hyperpolarized 13C signal overlaid on T2-weighted anatomic images; Figure S3: Tumor HP 13C LacAUC/
Pyrmax ratios, without 1H ADC normalization and 1H ADC in the three orthotopic tumors; Figure S4: mRNA
expression of RCC cells grown in 2D culture; Figure S5: Assessing cellularity from H&E images using a multi-step
CellProfiler pipeline; Figure S6: Image analysis of MCT4 staining using Matlab image analysis toolbox; Table S1:
Tumor characteristics.
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